Open AccessA randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
Author(s) -
Shufen Li,
Meng Wang,
Zhang Jibo,
Xiaojuan Xie,
Chunfang Hao,
Yongsheng Jia,
Zhongsheng Tong
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_792_19
Subject(s) - capecitabine , vinorelbine , docetaxel , anthracycline , medicine , metastatic breast cancer , oncology , breast cancer , randomized controlled trial , cancer , chemotherapy , colorectal cancer , cisplatin
Previous studies have shown that vinorelbine/capecitabine (NX) and docetaxel/capecitabine (TX) chemotherapy has a certain effect in advanced breast cancer. However, there are few clinical studies directly comparing TX and NX regimen chemotherapy, especially in patients with advanced breast cancer previously treated with anthracycline and taxane. The purpose of this Phase II study was to compare survival and side effects between patients with anthracycline- and taxane-resistant advanced breast cancer treated with NX and those treated with TX chemotherapy.